Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
Biogen currently co-markets Sage’s postpartum depression (PPD) drug Zurzuvae (zuranolone). Despite rejecting the offer, Sage’s board has stated it will consider “strategic alternatives” to ...
Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...
Biogen and Sage co-developed Zurzuvae, which was approved by the FDA for PPD in August 2023. Sage has experienced several setbacks since this approval. Zurzuvae did not win approval as a treatment ...
Sage Therapeutics Inc (SAGE) reports significant prescription growth for ZURZUVAE, despite a net loss and strategic ...
Based on the Company’s current operating plan, Sage anticipates that its existing cash, cash equivalents, and marketable ...
In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
“We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we ...
Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
Sage is focused on the goal of establishing ZURZUVAE as the standard of care for women with postpartum depression (PPD). The current commercialization investment plan includes joint sales force ...